Ipamorelin vs HGH: Growth Hormone Research Comparison
How researchers frame a selective ghrelin receptor agonist against full human growth hormone in body composition and GH axis studies
Ipamorelin and human growth hormone (HGH) both stimulate GH-axis-related physiological effects but through entirely different mechanisms at different points in the GH regulatory pathway. Ipamorelin is a selective ghrelin receptor agonist that stimulates pituitary GH release indirectly while preserving feedback regulation. HGH is the hormone itself, acting directly on peripheral GH receptors throughout the body. Researchers studying growth hormone biology, body composition, or aging select between these based on whether they need to study GH secretagogue pharmacology or the downstream effects of GH receptor activation.
At a Glance
Mechanism and research profile for each compound.
Ipamorelin
Ipamorelin is a selective pentapeptide agonist of the ghrelin receptor (GHS-R1a) that stimulates pituitary somatotroph cells to release growth hormone. It produces GH release with minimal cortisol or prolactin elevation compared to other GHS-R agonists. The somatostatin negative feedback loop remains active, preserving physiological regulation of GH levels.
Human Growth Hormone (HGH)
Recombinant human growth hormone (somatropin) acts directly on GH receptors in liver, muscle, adipose, and bone tissue, stimulating IGF-1 production (anabolic signaling), lipolysis, glucose regulation, and skeletal growth. It bypasses pituitary regulation entirely, activating GH receptors throughout the body regardless of somatostatin feedback status.
Key Differences
Side-by-side comparison of key research parameters.
| Aspect | Ipamorelin | Human Growth Hormone (HGH) |
|---|---|---|
| Level of Action | Pituitary level; stimulates GH secretion via ghrelin receptor | Peripheral level; directly activates GH receptors in liver, muscle, adipose |
| Feedback Preservation | Somatostatin negative feedback remains intact; self-regulating GH pulse | Bypasses pituitary feedback entirely; GH receptor activation independent of regulatory status |
| IGF-1 Elevation | Indirect; IGF-1 rises as a consequence of pituitary GH release, within physiological range | Direct and dose-dependent; IGF-1 elevation can be supraphysiological at high doses |
| Selectivity | High selectivity for GHS-R1a; minimal cortisol or prolactin effects vs other GHRP compounds | Non-selective; activates all GH receptors in all tissues equally at pharmacological doses |
| Regulatory Status | Research compound; not FDA approved as pharmaceutical | Multiple FDA-approved recombinant HGH forms (somatropin) for various indications |
Research Comparison
The fundamental research distinction is at what level of the GH axis the compound acts. Ipamorelin stimulates pituitary GH release while preserving feedback regulation, making it useful for research examining GH secretagogue pharmacology and physiological GH axis modulation. HGH activates GH receptors directly, bypassing pituitary regulation and producing direct anabolic and metabolic effects regardless of the regulatory feedback loop state. Researchers studying the regulatory biology of the GH axis choose Ipamorelin; researchers studying downstream GH receptor-mediated physiology choose HGH.
Frequently Asked Questions
Explore the Research
Ipamorelin is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply. For in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.